EPCAM and neoplasm: Interestingly, both flow cytometric analysis and immunohistochemical analysis of xenograft tumors revealed that metformin significantly reduced the number of tumor-initiating EpCAM+ cells, whereas sorafenib treatment had minimal effects on TICs.